Prof Timothy Perren explains the results of the ICON7 trial investigating the use of bevacizumab to treat advanced ovarian cancer. This trial compared standard chemotherapy of carboplatin and paclitaxel with a treatment programme of carboplatin, paclitaxel and bevacizumab. Disease progression was found to be delayed and occurred less frequently in the bevacizumab group. Prof Perren discusses how representative the patient population was, considers the effect of residual disease status and outlines some of the side effects. The number of patients being treated with upfront chemotherapy in place of surgery has recently been increasing; Prof Perren talks about the difficulties that will need to be overcome in any trial investigating the addition of bevacizumab to upfront chemotherapy. Prof Timothy Perren of Leeds Teaching Hospitals NHS Trust in the UK, speaking to ecancer.tv at the 2010 ESMO congress in Milan, Italy
http://www.youtube.com/watch?v=nbwCPS_btAs&hl=en
No comments:
Post a Comment